HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cantillon, M. Articles by Bahro, M. Search for Related Content PubMed Articles by Cantillon, M. Articles by Bahro, M.

Buspirone vs. Haloperidol

A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease

From the Section on Geriatric Psychiatry, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892.

The authors report on a pilot double-blind comparison of buspirone with haloperidol in the treatment of agitation manifested by physical tension and motor activity in Alzheimer's disease (AD). A group of 26 nursing home residents underwent a 10-week comparison of 15 mg buspirone (n = 12) vs. 1.5 mg haloperidol (n = 14) per day. Tension and anxiety decreased to a greater extent in those patients who were treated with buspirone. Although it is not possible to draw definitive conclusions from a treatment study that does not include a placebo group, these findings suggest the potential value of further clinical research on buspirone in managing agitation in AD.